Edition:
United States

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

13.22USD
4:00pm EDT
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$13.22
Open
$13.19
Day's High
$13.32
Day's Low
$12.96
Volume
1,872,238
Avg. Vol
668,824
52-wk High
$33.61
52-wk Low
$10.76

Select another date:

Tue, Jul 31 2018

Akorn row overshadows Fresenius' generics guidance

BERLIN Fears that a legal dispute with U.S. drugmaker Akorn could extend into next year overshadowed improved guidance from Germany's Fresenius SE for its Kabi generics business.

Fresenius CEO defends canceled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

UPDATE 1-Fresenius CEO defends cancelled Akorn deal

* Expects legal proceedings to conclude in 2019 (Adds details on expenses, comment on provision, analyst)

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN, May 18 Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

Fresenius sees Akorn lawsuit dragging on into 2019

BERLIN German healthcare group Fresenius SE said on Thursday its legal battle with Akorn over its canceled $4.7 billion takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro.

UPDATE 1-Fresenius sees Akorn lawsuit dragging on into 2019

* Net income 450 mln euro vs 437 mln f'cast in poll (Releads with Akorn comments)

Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

UPDATE 3-Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK, May 2 German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

BRIEF-Del. Court says Akorn-Fresenius Trial To Begin July 9

* DELAWARE COURT ORDERS AKORN-FRESENIUS TRIAL TO BEGIN JULY 9, WILL LAST ONE WEEK Further company coverage: (Reporting By Michael Erman)

Fresenius alleges "blatant fraud" at abandoned target Akorn

WILMINGTON, Del., May 2 German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a filing in Delaware's Court of Chancery.

Select another date: